Uvax Bio Announces Dosing of First Participant in Phase 1 Clinical Trial Evaluating Two Vaccines to Prevent HIV-1 Infection
Study to assess safety and immunogenicity of novel protein nanoparticle vaccine candidates UVAX-1107 and UVAX-1197 in healthy volunteers